his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

We've had our Eyes On recent data releases, commercial strategy updates, and some FDA updates. What caught your Eye last week?

The ASCO 2024 annual meeting took place from 31st May to 4th June. A number of firms presented data, and others used this as an opportunity

Check out this Top Drugs of 2023 list with links to interesting reports in PharmaTell Studio. Contact us for a trial.

This week we've had eyes on BioPharma happenings plus a 2023 Top Selling Drugs list.

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..